医疗信息平台OpenEvidence获得A轮融资，用于培训其下一代LLM-动脉网

Medical information platform OpenEvidence reaches $1B valuation

MobiHealthNews 等信源发布 2025-02-21 20:05



可切换为仅中文







Photo: Hero Images/Getty Images

照片来源：Hero Images/Getty Images

OpenEvidence, an AI-enabled medical research aggregate platform for doctors, has closed a Series A funding round with Sequoia Capital, boosting its valuation to $1 billion and bringing its total raise to more than $100 million.

OpenEvidence 是一个面向医生的 AI 医学研究聚合平台，已完成由红杉资本领投的 A 轮融资，其估值提升至 10 亿美元，总融资额超过 1 亿美元。

WHAT IT DOES

它的作用

OpenEvidence is a free medical information platform that offers an AI-enabled medical copilot for doctors in the U.S. It aggregates and synthesizes clinical evidence to help doctors make more evidence-based decisions.

OpenEvidence 是一个免费的医疗信息平台，为美国的医生提供人工智能支持的医疗助手。它汇总并综合临床证据，帮助医生做出更多基于证据的决策。

The company's AI is trained on specialized content through strategic collaborations, including a newly announced partnership with The New England Journal of Medicine.

该公司通过战略合作对其人工智能进行专业内容的训练，其中包括与《新英格兰医学杂志》新宣布的合作关系。

Through the partnership, all NEJM content from 1990 forward will be provided to OpenEvidence to help inform the answers provided to providers on its platform.

通过此次合作，所有自1990年以来的《新英格兰医学杂志》内容将提供给OpenEvidence，以帮助为其平台上的供应商提供的答案提供信息支持。

OpenEvidence was launched from the Mayo Clinic Platform Accelerator program.

OpenEvidence 是从梅奥诊所平台加速器项目启动的。

The funds will be used to train its next-generation LLMs and grow its team of scientists working at the intersection of LLMs and medicine. It will also use the investment to develop strategic content partnerships and work with medical researchers to grow its library.

这笔资金将用于训练其下一代LLM，并扩充其在LLM和医学交叉领域工作的科学家团队。该公司还将利用这笔投资发展战略内容合作伙伴关系，并与医学研究人员合作以扩充其资料库。

'As we come upon our platform's two-year anniversary later this spring, OpenEvidence is trusted and used daily by hundreds of thousands of doctors. But we're just getting started,' Daniel Nadler, founder of OpenEvidence, said in a statement.

“随着我们即将在今年春季晚些时候迎来平台两周年的纪念日，OpenEvidence 已经被数十万名医生每日信赖和使用。但我们才刚刚开始，”OpenEvidence 创始人丹尼尔·纳德勒在一份声明中说道。

'Our Series A with Sequoia will enable OpenEvidence to continue building the most trusted AI platform for doctors and other medical professionals in the world.'

“我们与红杉资本的A轮融资将使OpenEvidence能够继续打造全球最受医生和其他医疗专业人士信赖的AI平台。”

MARKET SNAPSHOT

市场概况

In 2023, a

2023年，一个

study

学习

revealed that OpenEvidence's AI scored over 90% on the United States Medical Licensing Examination (USMLE), making 77% fewer errors than ChatGPT, 24% fewer than GPT-4 and 31% fewer errors than Google's Med-PaLM 2.

揭示了OpenEvidence的AI在美国医学执照考试（USMLE）中得分超过90%，比ChatGPT少犯77%的错误，比GPT-4少24%，比谷歌的Med-PaLM 2少31%的错误。

Last year, Saurabh Gombar, adjunct faculty at

去年，萨拉布·戈姆巴尔（Saurabh Gombar），兼职教员

Stanford Healthcare

斯坦福医疗保健

and chief medical officer at

并且是首席医疗官

Atropos Health

阿特罗波斯健康

，

joined HIMSS TV

加入HIMSS TV

to discuss a study that analyzed the accuracy and efficacy of five LLMs, including OpenEvidence and ChatRWD.

讨论一项分析了五个LLM的准确性和有效性研究，其中包括OpenEvidence和ChatRWD。

'OpenEvidence and ChatRWD were able to produce actionable, reliable evidence either 42% or 60% of the time – an entire magnitude greater than the general purpose LLMs,' Gombar said.

“OpenEvidence 和 ChatRWD 能够在 42% 或 60% 的时间内生成可操作、可靠的证据，比通用大型语言模型高出整整一个数量级，”戈姆巴尔表示。

Tags:

标签：

OpenEvidence

打开证据

，

medical research aggregate

医学研究聚合

，

LLMs

大型语言模型

More regional news